Powered by

As ASCO 2021 Spotlights Biomarkers, New InCrowd Data Shows 80% of US Oncologists Anticipate Broader Liquid Biomarkers Use, Despite Insurance Barriers; While crediting life science firms that present a strong and transparent approach to biomarkers, 42% say

Jun 02, 2021 - Business Wire
Mergers and Acquisitions

With oncology biomarker testing advances featuring prominently in this week's American Society of Clinical Oncology ( ASCO 2021 ) agenda, new data show that 80% of US oncologists surveyed think liquid biomarker testing in the solid tumor space will increase from the estimated one-third of their solid tumor testing today. While 71% cite insurance coverage as the biggest barrier to biomarker targeted testing, oncologists see an important role for the pharmaceutical industry, with 42% of oncologist...